Aeterna Zentaris (NASDAQ:AEZS) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a report released on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Performance

NASDAQ:AEZS opened at $1.97 on Tuesday. The company has a market capitalization of $9.57 million, a price-to-earnings ratio of -0.58 and a beta of 1.57. Aeterna Zentaris has a one year low of $1.36 and a one year high of $3.30. The stock has a 50-day simple moving average of $1.98 and a 200 day simple moving average of $1.89.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last posted its quarterly earnings results on Wednesday, March 27th. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.19). The firm had revenue of $0.12 million for the quarter. Aeterna Zentaris had a negative net margin of 368.01% and a negative return on equity of 63.20%.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.